Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Diabetes candidate ARRY-403 to advance to clinical investigation

Oct. 15, 2008

IGF-I elevations last over one week after single injection of NNC-126-0083

Oct. 15, 2008

Ostarine meets primary endpoint in phase II cancer cachexia trial

Oct. 14, 2008

Natural extract derivative found as novel PDE5A1 inhibitor with better selectivity than sildenafil

Oct. 14, 2008

Biodel to meet with FDA by end of January 2009 to discuss NDA for diabetes drug VIAject

Oct. 14, 2008

Recent Plexxikon and Janssen patents impart novel antiobesity drugs

Oct. 14, 2008

MDRNA selects MDR-04227 as lead candidate in hypercholesterolemia program

Oct. 14, 2008

Lev receives FDA approval for Cinryze in hereditary angioedema prophylaxis

Oct. 13, 2008

Santarus commences marketing campaign for Glumetza

Oct. 13, 2008

FDA continues review of Takeda's NDA for alogliptin for type 2 diabetes

Oct. 13, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...